Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 4/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217697 | 0.91 | MAPT (0.60) | MAPTUSP2MAPK1HRH3KDM4E | |
| SCHEMBL218440 | 0.91 | MAPT (0.57) | MAPTUSP2MAPK1HRH3KDM4E | |
| SCHEMBL220192 | 0.91 | MAPT (0.60) | MAPTUSP2MAPK1HRH3KDM4E | |
| SCHEMBL219223 | 0.91 | MAPT (0.57) | MAPTUSP2MAPK1HRH3KDM4E | |
| SCHEMBL217101 | 0.89 | MAPT (0.56) | MAPTUSP2MAPK1HRH3KDM4E | |
| SCHEMBL220244 | 0.89 | USP2 (0.58) | MAPTUSP2MAPK1HRH3KDM4E | |
| SCHEMBL220243 | 0.89 | USP2 (0.58) | MAPTUSP2MAPK1HRH3KDM4E | |
| SCHEMBL216758 | 0.89 | MAPT (0.55) | MAPTUSP2MAPK1HRH3KDM4E | |
| SCHEMBL16384605 | 0.89 | MAPT (0.55) | MAPTUSP2MAPK1HRH3KDM4E | |
| SCHEMBL16380827 | 0.89 | MAPT (0.55) | MAPTUSP2MAPK1HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088758-B2 | 17β-hydroxysteroid dehydrogenase type I inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| EP-1685150-B1 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARM GMBH (DE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1685150-A2 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
| WO-2005047303-A2 | NOVEL 17β HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | HSD17B11, HSD17B1, HSD17B3 | MAPT 3025/4885USP2 1907/4885MAPK1 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.